Noveome Biotherapeutics welcomes Eric Keller and Dr. Houman Hemmati to its Board of Directors

– USA, PA –  Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, today announced the appointment of Eric Keller JD and Dr. Houman Hemmati (M.D., Ph.D.) to its Board of Directors.

“We are delighted to welcome Eric and Houman to our Board of Directors. Their vast experience in the scientific, legal, and business aspects of late-stage drug development will provide significant value to Noveome as we focus our efforts on our most promising therapeutic targets,” said Acting CEO and current Board member, Patrick Welch,

About Eric Keller

Eric Keller is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies. He is the Founder and CEO of Redux Therapeutics, LLC, a clinical-stage small molecule drug development company; Co-Founder and Head of Strategy at C2Sense, an MIT-based medical diagnostic company; EVP of SGH2 Energy Global, a developer and operator of waste to green hydrogen projects; and Strategic Advisor and CBO of SipNose, Ltd., a pioneering Israeli company delivering drugs direct nose-to-brain to treat a variety of CNS and other brain-related disorders.

About Dr. Houman D. Hemmati

Dr. Houman Hemmati is a board-certified ophthalmologist and leader in translational and late-stage drug development. He is presently the CMO of Vyluma, Inc., which is developing a pharmacologic treatment for nearsightedness (myopia). He is also Co-Founder and CSO of aesthetic medicine company Levation Pharma and retina therapeutics company Optigo Biotherapeutics, which is developing long-acting intravitreal drugs for wet macular degeneration and diabetic eye disease. Additionally, he is on the Board of Directors of Trailhead Biosystems (stem cells) and MediPrint Ophthalmics (contact lens drug delivery) and advises a handful of companies in ophthalmology drug development. He previously served as Director, Clinical Development at Allergan, and as Clinical Scientist in the Ophthalmology Therapeutic Area on several Phase 1, 2, and 3 studies, including the Phase 2 study for the program that led to the approval of Vuity to treat presbyopia.

About Noveome Biotherapeutics, Inc.

Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects. ST266 also completed a Phase 1 open-label clinical trial establishing the safety of ST266 in intranasal transcribriform delivery from nose-to-brain and eye, and a Phase 1 clinical trial establishing the safety of intravenously administered ST266 in COVID-19 patients.

For more information: https://noveome.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.